BD rises 1.7% on earnings beat as Waters deal transforms company
Medical technology giant completes $4 billion transaction, affirms 'New BD' strategy with fiscal 2026 guidance
Becton Dickinson shares rose 1.7% in pre-market trading Monday after the medical technology giant reported stronger-than-expected first-quarter earnings and completed a transformative $4 billion transaction with Waters Corporation, marking a pivotal moment in the company's strategic evolution.
The Franklin Lakes, New Jersey-based company reported fiscal first-quarter revenue of $5.3 billion, representing a 1.6% increase year-over-year and exceeding analyst consensus estimates of approximately $5.15 billion. Adjusted diluted earnings per share reached $2.91, surpassing Wall Street projections of $2.81, according to multiple analyst reports ahead of the earnings release.
Tom Polen, chairman, CEO and president of BD, attributed the stronger performance to "disciplined execution, accelerated commercial initiatives, and broad-based growth across key end markets." The results, announced in the company's press release, come as BD completes what executives have termed a significant milestone in its "New BD" strategy—a focused pivot to medical technology leadership.
The Waters transaction, which closed Monday, involves BD receiving $4 billion in cash while BD shareholders retain a 39.2% stake in the combined entity on a fully diluted basis. The newly combined company, valued at approximately $17.5 billion, will operate as a diversified leader in life sciences and diagnostics, expanding Waters' total addressable market to roughly $40 billion. Existing Waters shareholders own 60.8% of the combined company.
"This transaction establishes 'New BD' as a focused MedTech leader, accelerating innovation in medical technology," the company stated in pre-earnings commentary. The strategic separation allows BD to concentrate resources on its core medical technology businesses while the life sciences and diagnostics operations gain scale and focus under the Waters banner.
BD affirmed its fiscal year 2026 guidance for the streamlined "New BD" entity, projecting GAAP revenue growth in the low single-digit range with adjusted diluted earnings per share of $12.35 to $12.65. The guidance specifically reflects the performance of the company following the separation of its Biosciences and Diagnostic Solutions business, according to analyst summaries of the earnings call.
The earnings beat comes at a critical juncture for the $59.8 billion market capitalization company, which has faced questions about growth trajectories amid broader healthcare sector pressures. The stock currently trades at a forward price-to-earnings ratio of 14.1, significantly below its trailing P/E of 36.1—a multiple that reflects the market's anticipation of the strategic transformation rather than historical performance.
Analysts have largely maintained constructive ratings on the shares heading into the transaction close. The current consensus target price of $211.92 suggests modest upside from current levels, with 2 analysts rating the stock a strong buy, 3 recommending buy, and 9 at hold, according to market data. Institutional ownership remains high at 95.6%, indicating continued confidence from sophisticated investors.
The Waters deal completion removes a key overhang for investors, who have been awaiting clarity on the company's post-separation financial structure and strategic positioning. With $4 billion in cash proceeds from the transaction, BD now has enhanced flexibility to invest in core MedTech innovation, pursue selective acquisitions, or return capital to shareholders.
Looking ahead, investors will focus on BD's ability to execute on its "New BD" strategy, particularly its innovation pipeline and commercial execution in key medical technology segments. The company's affirmed guidance for low single-digit revenue growth suggests management confidence in achieving its objectives despite challenging macro conditions in healthcare markets globally.